Scaffold hopping of fused piperidine-type NK3 receptor antagonists to reduce environmental impact

被引：1
|
作者：
Yamamoto, Koki [1 ]
Inuki, Shinsuke [1 ]
Ohno, Hiroaki [1 ]
Oishi, Shinya [1 ]
机构：
[1] Kyoto Univ, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan
来源：
BIOORGANIC & MEDICINAL CHEMISTRY | 2019年 / 27卷 / 10期
关键词：
Environmental impact; Fezolinetant; GnRH; NK3; receptor; Scaffold hopping; WATER TREATMENT-PLANT; HUMAN NEUROKININ-3 RECEPTOR; PHARMACEUTICALS; KISSPEPTIN; SECRETION; HORMONES; FATE; GNRH; PHOTODEGRADATION; IDENTIFICATION;
D O I：
10.1016/j.bmc.2019.03.059
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Neurokinin-3 receptor (NK3R) plays a pivotal role in the release of gonadotropin-releasing hormone in the hypothalamus-pituitary-gonadal (HPG) axis. To develop novel NK3R antagonists with less environmental toxicity, a series of heterocyclic scaffolds for the triazolopiperazine substructure in an NK3R antagonist fezoli-netant were designed and synthesized. An isoxazolo[3,4-c]piperidine derivative exhibited moderate NK3R antagonistic activity and favorable properties that were decomposable under environmental conditions.
引用
收藏
页码：2019 / 2026
页数：8
相关论文
共 45 条
  • [31] Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor (vol 21, pg 1991, 2011)
    Hoveyda, Hamid R.
    Roy, Marie-Odile
    Blanc, Sebastien
    Noel, Sophie
    Salvino, Joseph M.
    Ator, Mark A.
    Fraser, Graeme
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (23) : 7228 - 7228
  • [32] Isoquinolinone-4-carboxamides as NK3 receptor antagonists: Discovery of development candidate Lu AE61035
    Juhl, Karsten
    Khanzhin, Nikolay A.
    Bundgaard, Christoffer
    Larsen, Dorrit B.
    Steiniger-Brach, Bjorn
    Nielsen, Soren M.
    Simonsen, Klaus B.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246
  • [33] Nonchromatographic Isolation of 2-Alkyl-2H-1,2,3-Triazoles in the Synthesis of NK3 Receptor Antagonists
    Wang, Huan
    Yin, Hao
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2010, 14 (02) : 474 - 476
  • [34] Design and synthesis of a novel series of histamine H3 receptor antagonists through a scaffold hopping strategy
    Gao, Zhongli
    Hurst, William J.
    Hall, Daniel
    Hartung, Ryan
    Reynolds, William
    Kang, Jiesheng
    Nagorny, Raisa
    Hendrix, James A.
    George, Pascal G.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2015, 23 (03) : 429 - 438
  • [35] III. Identification of novel CXCR3 chemokine receptor antagonists with a pyrazinyl-piperazinyl-piperidine scaffold
    Kim, Seong Heon
    Anilkumar, Gopinadhan N.
    Zawacki, Lisa Guise
    Zeng, Qingbei
    Yang, De-Yi
    Shao, Yuefei
    Dong, Guizhen
    Xu, Xiaolian
    Yu, Wensheng
    Jiang, Yueheng
    Jenh, Chung-Her
    Hall, James W., III
    Carroll, Carolyn DiIanni
    Hobbs, Doug W.
    Baldwin, John J.
    McGuinness, Brian F.
    Rosenblum, Stuart B.
    Kozlowski, Joseph A.
    Shankar, Bandarpalle B.
    Shih, Neng-Yang
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (23) : 6982 - 6986
  • [36] Expression of the neurokinin-3 (nk3) receptor in off-type cone bipolar cells in mouse retina
    Hirano, AA
    Brecha, NC
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2002, 43 : U159 - U159
  • [37] Antidepressant-type effect of the NK3 tachykinin receptor agonist aminosenktide in mouse lines differing in endogenous opioid system activity
    Panocka, I
    Massi, M
    Lapo, I
    Swiderski, T
    Kowalczyk, M
    Sadowski, B
    PEPTIDES, 2001, 22 (07) : 1037 - 1042
  • [38] Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold
    Vaccaro, WD
    Sher, R
    Berlin, M
    Shih, NY
    Aslanian, R
    Schwerdt, JH
    McCormick, KD
    Piwinski, JJ
    West, RE
    Anthes, JC
    Williams, SM
    Wu, RL
    She, HS
    Rivelli, MA
    Mutter, JC
    Corboz, MR
    Hey, JA
    Favreau, L
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (02) : 395 - 399
  • [39] In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics
    Dawson, Lee A.
    Langmead, Christopher J.
    Dada, Adeshola
    Watson, Jeannette M.
    Wu, Zining
    de la Flor, Raul
    Jones, Gareth A.
    Cluderay, Jane E.
    Southam, Eric
    Murkitt, Graham S.
    Hill, Mark D.
    Jones, Declan N. C.
    Davies, Ceri H.
    Hagan, Jim J.
    Smith, Paul W.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2010, 627 (1-3) : 106 - 114
  • [40] Hyperresponsiveness to the tachykinin NK1 receptor agonist [SAR9, Met(O2)11]SP after IL-1β pretreatment and passive sensitization of human isolated bronchi:: Effects of tachykinin NK2 and NK3 receptor antagonists.
    Vincent, F
    Naline, E
    Molimard, M
    Daoui, S
    Vilain, P
    Emonds-Alt, X
    Advenier, C
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A281 - A281
12345